Ország: Írország
Nyelv: angol
Forrás: HPRA (Health Products Regulatory Authority)
ROPINIROLE HYDROCHLORIDE
GlaxoSmithKline (Ireland) Limited
ROPINIROLE HYDROCHLORIDE
0.5 Milligram
Film Coated Tablet
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
_ _ 1 PACKAGE LEAFLET: INFORMATION FOR THE USER REQUIP 0.25 MG FILM-COATED TABLETS REQUIP 0.5 MG FILM-COATED TABLETS REQUIP 1 MG FILM-COATED TABLETS REQUIP 2 MG FILM-COATED TABLETS REQUIP 5 MG FILM-COATED TABLETS Ropinirole (as hydrochloride) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. Keep this leaflet. You may need to read it again. If you have any more questions, ask your doctor or pharmacist (chemist). IF YOU GET ANY SIDE EFFECTS, TALK TO YOUR DOCTOR OR PHARMACIST. THIS INCLUDES ANY POSSIBLE SIDE EFFECTS NOT LISTED IN THIS LEAFLET. WHAT IS IN THIS LEAFLET 1 WHAT REQUIP IS AND WHAT IT IS USED FOR 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE REQUIP 3 HOW TO TAKE REQUIP 4 POSSIBLE SIDE EFFECTS 5 HOW TO STORE REQUIP 6 CONTENTS OF THE PACK AND OTHER INFORMATION 1 WHAT REQUIP IS AND WHAT IT IS USED FOR The active ingredient in Requip is ropinirole, which belongs to a group of medicines called DOPAMINE AGONISTS. Dopamine agonists affect the brain in a similar way to a natural substance called dopamine. REQUIP IS USED TO TREAT PARKINSON’S DISEASE. People with Parkinson’s disease have low levels of dopamine in some parts of their brains. Ropinirole has effects similar to those of natural dopamine, so it helps to reduce the symptoms of Parkinson’s disease. 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE REQUIP DO NOT TAKE REQUIP: if you are ALLERGIC (hypersensitive) to ropinirole or any of the other ingredients of this medicine (listed in sections 4 and 6) if you have SERIOUS KIDNEY DISEASE if you have LIVER DISEASE TELL YOUR DOCTOR if you Olvassa el a teljes dokumentumot
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Requip 0.5 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 0.5 mg of ropinirole as ropinirole hydrochloride. Excipient: 45.0 mg lactose For the full list of excipients, see section 6.1_._ 3 PHARMACEUTICAL FORM Film-coated tablet. Yellow, pentagonal-shaped bevelled edge tablets marked “SB” on one side and “4891” on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of Parkinson's disease under the following conditions: o Initial treatment as monotherapy, in order to delay the introduction of levodopa o In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral use. Adults Individual dose titration against efficacy and tolerability is recommended. Requip should be taken three times a day, preferably with meals to improve gastrointestinal tolerance. _Treatment initiation_ The initial dose of ropinirole should be 0.25 mg three times daily for 1 week. Thereafter, the dose of ropinirole can be increased in 0.25 mg three times daily increments, according to the following regimen: _Therapeutic regimen_ After the initial titration, weekly increments of 0.5 to 1 mg three times daily (1.5 to 3 mg/day) of ropinirole may be given. A therapeutic response may be seen between 3 and 9 mg/day of ropinirole. If sufficient symptomatic control is not achieved, or maintained after the initial titration as described above, the dose of ropinirole may be increased up to 24 mg/day. Week 1 2 3 4 Unit dose (mg) of ropinirole 0.25 0.5 0.75 1.0 Total daily dose ( Olvassa el a teljes dokumentumot